Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 13/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.42 |
| ▸ | PLG | P00747 | 5/20 | 0.38 |
| ▸ | PLAT | P00750 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.35 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.35 |
| ▸ | SPPL2A | Q8TCT8 | 1/20 | 0.35 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.35 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.35 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.35 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6436527 | 1.00 | PLAU (0.46) | PLAUDAGLAPLGPLATLMNA | |
| SCHEMBL6433781 | 0.87 | PLAU (0.45) | PLAUDAGLAPLGPLATLMNA | |
| SCHEMBL6433756 | 0.87 | PLAU (0.45) | PLAUDAGLAPLGPLATLMNA | |
| SCHEMBL6433083 | 0.83 | PLAU (0.57) | PLAUPLGPLATLMNASMN1; SMN2 | |
| SCHEMBL6434229 | 0.82 | PLAU (0.54) | PLAUPLGPLAT | |
| SCHEMBL6433131 | 0.82 | PLAU (0.58) | PLAUDAGLAPLGSMN1; SMN2TAS2R14 | |
| SCHEMBL6432860 | 0.80 | PLAU (0.61) | PLAU | |
| SCHEMBL6432952 | 0.78 | PLAU (0.47) | PLAUPLGSMN1; SMN2 | |
| SCHEMBL6434727 | 0.78 | PLAU (0.45) | PLAUPLGPLATLMNASMN1; SMN2 | |
| SCHEMBL6438243 | 0.77 | TP53 (0.45) | PLAULMNASMN1; SMN2TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1077945-B1 | ISOQUINOLINES AS UROKINASE INHIBITORS | PFIZER (US) | 2003-01-08 | — | — | EP | disclosed |
| US-6093731-A | Isoquinolines | PFIZER INC. | 2000-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885DAGLA 806/4885PLG 33/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885DAGLA 806/4885PLG 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.